The Guardant360 test can provide comprehensive genomic profiling information which helps to guide treatment decisions for advanced lung cancer patients. In this patient case, the Guardant360 test detected an uncommon exon 19 deletion that was not included in hotspot polymerase chain reaction (PCR) testing. An actionable mutation, EGFR T751_I759delinsN, was detected. As a result, a planned repeat biopsy for this 60-year-old patient was cancelled. He was treated with the right precision medicine, osimertinib, and responded well to treatment. This is an actual patient case, but the image and name are not real to maintain patient’s confidentiality.

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at [email protected] or contact us on
WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.